Chinese SDA (State Drug Administration) gets EU regulatory update:
This article was originally published in Clinica
The latest regulatory developments in the EU and China will be on the agenda when officials from the Chinese State Drug Administration visit the European device industry association, Eucomed, on September 19-20 2002. The Chinese delegation, led by SDA medical devices registration division director Chang Yongheng, will also meet DG Enterprise officials, UK notified body BSI and the MDA during their brief tour. The Chinese medial devices market is valued by the US Department of Commerce at $5.2bn, $1.4bn of which (in 2000) was provided by imports. Imports grew by 15.5% that year, says Eucomed.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.